ER positive

P2, N=28, Completed, Xijing Hospital | Recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Feb 2026

P1, N=33, Recruiting, Halda Therapeutics OpCo, Inc.

In PREDIX LumB patients with estrogen receptor positive and human epidermal growth factor receptor negative (ER + /HER2-) breast cancer > 20 mm and/or with lymph node metastasis were randomized 1:1 to receive either paclitaxel weekly for 12 weeks followed by palbociclib and endocrine therapy for 12 weeks (arm A), or the reverse sequence (arm B). The predictive signature was independently validated in the CORALLEEN trial (pinteraction=0.048). Clinicaltrials.gov identifier: NCT02603679.

High expression of PAPP-A is associated with poor prognosis in ER+ breast cancer and correlates with IGF-1/IGF-1R pathway activation.

Both LAS52119664 and BBF30702300 emerged as novel and promising natural dual inhibitors of aromatase and CDK4/6, providing a basis for future experimental validation and the development of multitargeted therapies for ER-positive breast cancer.

In this retrospective cohort study, neoadjuvant 12wTCHP was well tolerated and associated with high pCR and low early recurrence rates. These findings are hypothesis-generating and support further evaluation of de-escalated 12wTCHP regimen in selected patients.

High MKI67 expression identifies highly proliferative tumors that are associated with genomic instability and immune activity and is associated with higher pCR rates following neoadjuvant chemotherapy in ER+/HER2- BC.

SOAT inhibition markedly reduced sodium-dependent DHEAS uptake, resulting in decreased intracellular estradiol synthesis and suppression of estrogen-dependent proliferation without cytotoxicity. These findings confirm that SOAT is a critical upstream regulator of intracrine estrogen biosynthesis in breast cancer cells and highlight compounds 12 and 24 as promising candidates for further preclinical development aimed at reducing local estrogen production.

ER-low breast cancer challenges the traditional binary classification of hormone receptor-positive/-negative disease. Diagnostic variability, biological heterogeneity, and therapeutic ambiguity justify the need for standardized pathological assessment, biomarker-driven stratification, and dedicated prospective trials to refine management and improve outcomes.

GHS/QoL and function were maintained across treatment arms, despite a higher incidence of diarrhea in the imlunestrant-abemaciclib group. These PRO findings complement the efficacy and safety results from EMBER-3 and further support the favorable risk-benefit profile of imlunestrant, either as oral monotherapy or in combination with abemaciclib, in patients with advanced breast cancer.

External beam radiotherapy is the gold standard for management of choroidal metastases. However, it appears that first-line treatment with endocrine therapy and CDK4/6 inhibitors in patients with ER+ and HER2- breast cancer is likely effective for the treatment of choroidal metastases secondary to ER+/HER2- breast cancer and may allow a delay in the use of local invasive interventions.

Detection was not feasible in MDA-MB-231 cells, a triple (-) breast cell line that does not express GIRK1. This is the first study, to our knowledge, that couples nanotechnology with small molecule drug design and electrophysiology to develop ion channel-tracing molecular probes for the detection/screening of ER+ breast cancer.